Barely Significant
← all excerpts

Treatment-related adverse effects with pazopanib, sorafenib and sunitinib in patients with advanced soft tissue sarcoma: a pooled analysis.

Cancer Manag Res · 2018 · PMC6055834 · PMID 30050324

Europe PMCDOI
1
hedged sentence
0.0230
closest p · 0.5× alpha
0.0230
boldest claim

The sentences

highly significantP =0.023actually significant
The difference was highly significant for sorafenib vs. pazopanib in the incidence of all-grade rash (odds ratio [OR] 1.649, 95% CI 1.086–2.505, P =0.023), hand–foot syndrome (OR 3.096, 95% CI 1.271–7.544, P =0.009) and mucositis (OR 4.562, 95% CI 2.132–9.609, P <0.001).

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.